[Myeloid neoplasms associated with rearrangement of PDGFRB: A rare and tricky disease]

Ann Pathol. 2022 Nov;42(6):481-487. doi: 10.1016/j.annpat.2022.03.005. Epub 2022 Aug 29.
[Article in French]

Abstract

In the latest World Health Organization classification (WHO), eosinophilic disorders represent a group of rare pathologic conditions with highly heterogeneous pathophysiology. In this report, we describe a case of myeloid neoplasm associated with eosinophilia and rearrangement of PDGFRB gene in a 67-year-old-male patient hospitalized with cerebellous ataxia. Initial investigations showed a bicytopenia with hypereosinophilia varying from 1.1 to 1.6×109/L. Bone marrow aspiration was rich and showed a heterogeneous distribution of myeloid cells with clusters of promyelocytes and proerythroblasts associated with numerous eosinophils and spindle-shaped mast cells but without excess of blasts, dysplasia nor maturation skewing. These aspects suggested an atypical myeloproliferative neoplasm. Bone marrow biopsy was performed showing also a very high cellularity with area of myeloid and erythroid precursors associated with numerous spindle-shaped mast cells. Diagnoses of unclassified myeloid neoplasm and/or systemic mastocytosis were then proposed. Further chromosome analysis showed a t(5;8) translocation with PDGFRB rearrangement revealed in fluorescent in situ hybridization. Patient was treated with imatinib and intravenous immunoglobulin therapy allowing a significant improvement in neurological symptoms and biological results. Patient condition is currently stable after six lines of treatment. This rare hematopoietic neoplasm displays unusual histological and cytological features and can mimic other myeloproliferative neoplasm. Specific cytogenetics analysis should be considered for such cases with hypereosinophilia to select patients that may benefit from targeted therapy.

Keywords: Bone marrow; Gene rearrangement; Hypereosinophilia; Hyperéosinophilie; Moelle osseuse; Myeloid neoplasm; Néoplasie myéloïde; PDGFRB; Réarrangement génique.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Aged
  • Eosinophilia* / diagnosis
  • Eosinophilia* / genetics
  • Eosinophilia* / therapy
  • Hematologic Neoplasms*
  • Humans
  • Imatinib Mesylate / therapeutic use
  • Immunoglobulins, Intravenous / genetics
  • In Situ Hybridization, Fluorescence
  • Male
  • Myeloproliferative Disorders* / complications
  • Myeloproliferative Disorders* / diagnosis
  • Myeloproliferative Disorders* / genetics
  • Receptor, Platelet-Derived Growth Factor beta / genetics

Substances

  • Receptor, Platelet-Derived Growth Factor beta
  • Imatinib Mesylate
  • Immunoglobulins, Intravenous
  • PDGFRB protein, human